Market buoyant; PSU, oil & gas stocks up
Tata Metaliks crashes
Tata Metaliks plunged 8.5% to Rs 115.70, after it reported a net loss in Q3 December 2006.As many as 9,812 shares changed hands in the counter on BSE.
The stock had witnessed a pre-results' rally. From Rs 110.05 on 3 January 2007, it had surged to Rs 126.50 by 17 January 2007. The results hit the market after trading hours on 17 January 2007.
Tata Metaliks reported a net loss of Rs 1.12 crore in Q3 December 2006, compared to a net profit of Rs 7.24 crore in Q3 December 2005. Net sales have surged to Rs 147.99 crore (Rs 92.64 crore).
The company said its blast furnace No. 1 at Kharagpur, was blown down on 15 October 2006. It was rebuilt for Rs 14.12 crore and commissioned on 6 December 2006.
Biocon zooms on pleasing Q3 results
Biocon jumped 20% to Rs 445.65, after its net profit for Q3 December 2006 increased 44.90%.The counter clocked 12.04 lakh shares on BSE, with pending buy orders of 12,319 shares at the maximum limit.
The stock had witnessed a steady rally in the past few days. From Rs 359.50 on 10 January, it rose to Rs 371.40 by 17 January 2007.
Biocon reported 44.90% rise in net profit for Q3 December 2006, to Rs 47.51 crore, compared to Rs 32.79 crore in net profit for Q3 December 2005. Net sales rose 24.20% to 214.08 crore (Rs 172.40 crore).
The company also granted an exclusive license to Ferozsons Laboratories for marketing BIOMAb EGFR in Pakistan. Many companies have evinced licensing interest for the proprietary cancer drug in the region after the successful debut made by BIOMAb EGFR in the Indian market. As per IMS data, Ferozsons is the No 1 national Oncology company in Pakistan.
The Pakistan oncology market is valued at approximately $70 million.
BIOMAb EGFR is indicated for head and neck cancer, and is being studied in global clinical trials for Colorectal, Lung Cancer, Glioma and Pancreatic cancers.
Biocon is a leading biopharmaceutical company with strong R&D capabilities in fermentation technology, biotechnology and drug discovery. The company is a pioneer in production of biopharmaceuticals through the fermentation route.
Tata Metaliks plunged 8.5% to Rs 115.70, after it reported a net loss in Q3 December 2006.As many as 9,812 shares changed hands in the counter on BSE.
The stock had witnessed a pre-results' rally. From Rs 110.05 on 3 January 2007, it had surged to Rs 126.50 by 17 January 2007. The results hit the market after trading hours on 17 January 2007.
Tata Metaliks reported a net loss of Rs 1.12 crore in Q3 December 2006, compared to a net profit of Rs 7.24 crore in Q3 December 2005. Net sales have surged to Rs 147.99 crore (Rs 92.64 crore).
The company said its blast furnace No. 1 at Kharagpur, was blown down on 15 October 2006. It was rebuilt for Rs 14.12 crore and commissioned on 6 December 2006.
Biocon zooms on pleasing Q3 results
Biocon jumped 20% to Rs 445.65, after its net profit for Q3 December 2006 increased 44.90%.The counter clocked 12.04 lakh shares on BSE, with pending buy orders of 12,319 shares at the maximum limit.
The stock had witnessed a steady rally in the past few days. From Rs 359.50 on 10 January, it rose to Rs 371.40 by 17 January 2007.
Biocon reported 44.90% rise in net profit for Q3 December 2006, to Rs 47.51 crore, compared to Rs 32.79 crore in net profit for Q3 December 2005. Net sales rose 24.20% to 214.08 crore (Rs 172.40 crore).
The company also granted an exclusive license to Ferozsons Laboratories for marketing BIOMAb EGFR in Pakistan. Many companies have evinced licensing interest for the proprietary cancer drug in the region after the successful debut made by BIOMAb EGFR in the Indian market. As per IMS data, Ferozsons is the No 1 national Oncology company in Pakistan.
The Pakistan oncology market is valued at approximately $70 million.
BIOMAb EGFR is indicated for head and neck cancer, and is being studied in global clinical trials for Colorectal, Lung Cancer, Glioma and Pancreatic cancers.
Biocon is a leading biopharmaceutical company with strong R&D capabilities in fermentation technology, biotechnology and drug discovery. The company is a pioneer in production of biopharmaceuticals through the fermentation route.
posted by SY at 12:42 PM
0 Comments:
Post a Comment
<< Home